

Center for Clinical and Genetic Economics

Duke Clinical Research Institute

Duke University School of Medicine, Durham, NC

<http://www.dcri.duke.edu/ccge/>

1. Weinfurt KP, Willke R, Glick HA, Schulman KA. Towards a composite scoring solution for the Neurobehavioral Functioning Inventory. *Qual Life Res.* 1999;8(1-2):17-24.
2. Glick HA, Polsky D, Willke RJ, Schulman KA. A comparison of preference assessment instruments used in a clinical trial: responses to the visual analog scale from the EuroQol EQ-5D and the Health Utilities Index. *Med Decis Making.* 1999;19(3):265-275.
3. Sheifer SE, Schulman KA. Racial differences in the use of invasive cardiac procedures: a continuous quality improvement approach. *Am Heart J.* 1999;138(3 Pt 1):396-399.
4. Weinfurt KP, Rathore SS, Schulman KA. ACI-TIPI clinical trial: acute cardiac ischemia time-insensitive predictive instrument. *Ann Intern Med.* 1999;131(6):476-477.
5. Freeman VG, Rathore SS, Weinfurt KP, Schulman KA, Sulmasy DP. Lying for patients: physician deception of third-party payers. *Arch Intern Med.* 1999;159(19):2263-2270.
6. Schulman KA, Mehta SS, Gersh BJ, Schneider EC, Wilcox CS. Study of Hypertensive Prescribing Practices (SHyPP): a national survey of primary care physicians. *J Clin Hypertens.* 1999;1(2):106-114.
7. Cai L, Weinfurt KP. An SAS/IML module for Johnson-Neyman procedure. *Appl Psych Meas.* 1999;23(4):308.
8. Bentham WD, Cai L, Schulman KA. Characteristics of hospitalizations of HIV-infected patients: an analysis of data from the 1994 Healthcare Cost and Utilization Project. *J Acquir Immune Defic Syndr.* 1999;22(5):503-508.
9. Winchester JF, Levine B, Collmann J, et al. Telemedicine: future promise for dialysis management. *Semin Dial.* 1999;12(Suppl 1):S101-S103.
10. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. *J Clin Oncol.* 2000;18(1):43-53.
11. Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin DJ, Rowland JH, Meropol NJ. Impact of quality of life on patient expectations regarding phase I clinical trials. *J Clin Oncol.* 2000;18(2):421-428.
12. Berger AK, Schulman KA, Gersh BJ. Primary angioplasty vs thrombolysis in elderly patients. *JAMA.* 2000;283(5):601-602.
13. Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. *Circulation.* 2000;101(9):969-974.
14. Weinfurt KP, Willke RJ, Glick HA, Freimuth WW, Schulman KA. Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. *Med Care.* 2000;38(4):404-410.
15. Rathore SS, Lenert LA, Weinfurt KP, et al. The effects of patient sex and race on medical students' ratings of quality of life. *Am J Med.* 2000;108(7):561-566.
16. Sheifer SE, Escarce JJ, Schulman KA. Race and sex differences in the management of coronary artery disease. *Am Heart J.* 2000;139(5):848-857.
17. Every NR, Maynard C, Schulman K, Ritchie JL. The association between institutional primary angioplasty procedure volume and outcome in elderly Americans. *J Invasive Cardiol.* 2000;12(6):303-308.
18. Sulmasy DP, Freeman VG, Schulman KA. The factuality of health records. *Arch Intern Med.* 2000;160(14):2224-2225.
19. Mandelblatt JS, Hadley J, Kerner JF, et al. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. *Cancer.* 2000;89(3):561-573.
20. Rathore SS, McGreevey JD, Schulman KA, Atkins D. Mandated coverage for cancer-screening services (2). Whose guidelines do states follow? *Am J Prev Med.* 2000;19(2):71-78.
21. Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. *Am J Hematol.* 2000;64(4):251-256.
22. Schulman KA, Kim JJ. Medical errors: how the US government is addressing the problem. *Curr Control Trials Cardiovasc Med.* 2000;1(1):35-37.
23. Rathore SS, Berger AK, Weinfurt KP, et al. Race, sex, poverty, and the medical treatment of acute myocardial infarction in the elderly. *Circulation.* 2000;102(6):642-648.
24. Sheifer SE, Rathore SS, Gersh BJ, et al. Time to presentation with acute myocardial infarction in the elderly: associations with race, sex, and socioeconomic characteristics. *Circulation.* 2000;102(14):1651-1656.
25. Kim J, Morris CB, Schulman KA. The role of the Food and Drug Administration in pharmacoeconomic evaluation during the drug development process. *Drug Inf J.* 2000;34(4):1207-1213.
26. Backhouse ME, Gnanasakthy A, Schulman KA, Akehurst R, Glick H. The development of standard economic datasets for use in the economic evaluation of medicines. *Drug Inf J.* 2000;34:1273-1291.
27. Einbinder LC, Schulman KA. The effect of race on the referral process for invasive cardiac procedures. *Med Care Res Rev.* 2000;57 Suppl 1:162-180.
28. Meehan KR, Areman EM, Ericson SG, Matias C, Seifeldin R, Schulman K. Mobilization, collection, and processing of autologous peripheral blood stem cells: development of a clinical process with associated costs. *J Hematother Stem Cell Res.* 2000;9(5):767-771.
29. Rathore SS, Gersh BJ, Berger PB, et al. Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes. *Am Heart J.* 2001;141(1):47-54.
30. Berger AK, Breall JA, Gersh BJ, et al. Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (The Cooperative Cardiovascular Project). *Am J Cardiol.* 2001;87(3):272-277.
31. Polsky D, Willke RJ, Scott K, Schulman KA, Glick HA. A comparison of scoring weights for the EuroQol derived from patients and the general public. *Health Econ.* 2001;10(1):27-37.
32. Rathore SS, Weinfurt KP, Gersh BJ, Oetgen WJ, Schulman KA, Solomon AJ. Treatment of patients with myocardial infarction who present with a paced rhythm. *Ann Intern Med.* 2001;134(8):644-651.
33. Polsky D, Weinfurt KP, Kaplan B, Kim J, Fastenau J, Schulman KA. An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. *Nephrol Dial Transplant.* 2001;16(5):1028-1033.
34. Weaver C, Schulman K, Buckner C. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. *Bone Marrow Transplant.* 2001;27(Suppl 2):S23-S29.
35. Rathore SS, Gersh BJ, Weinfurt KP, Oetgen WJ, Schulman KA, Solomon AJ. The role of reperfusion therapy in paced patients with acute myocardial infarction. *Am Heart J.* 2001;142(3):516-519.

36. DesHarnais Castel L, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. *Support Care Cancer*. 2001;9(7):545-551.
37. Seils DM, Friedman JY, Schulman KA. Sex differences in the referral process for invasive cardiac procedures. *J Am Med Womens Assoc*. 2001;56(4):151-154.
38. Schulman KA, Yabroff KR, Kong J, et al. A claims data approach to defining an episode of care. *Pharmacoepidemiol Drug Saf*. 2001;10(5):417-427.
39. Dranitsaris G, Castel LD, Baladi JF, Schulman KA. Zoledronic acid versus pamidronate as palliative therapy in cancer patients: a Canadian time and motion analysis. *J Oncol Pharm Pract*. 2001;7(1):27-33.
40. Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. *Diabetes Care*. 2001;24(8):1411-1415.
41. Weaver CH, Buckner CD, Curtis LH, et al. Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy. *Bone Marrow Transplant*. 2002;29(2):159-164.
42. Seils DM, Castel LD, Curtis LH, Weinfurt KP. Welfare reform and Latinas' use of perinatal health care. *Am J Public Health*. 2002;92(5):699-700.
43. Weinfurt KP, Trucco SM, Willke RJ, Schulman KA. Measuring agreement between patient and proxy responses to multidimensional health-related quality-of-life measures in clinical trials: an application of psychometric profile analysis. *J Clin Epidemiol*. 2002;55(6):608-618.
44. Gaskin DJ, Escarce JJ, Schulman K, Hadley J. The determinants of HMOs' contracting with hospitals for bypass surgery. *Health Serv Res*. 2002;37(4):963-984.
45. Schulman KA, Seils DM, Timbie JW, et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. *N Engl J Med*. 2002;347(17):1335-1341.
46. Polsky D, Keating NL, Weeks JC, Schulman KA. Patient choice of breast cancer treatment: impact on health state preferences. *Med Care*. 2002;40(11):1068-1079.
47. Curtis LH, Phelps CE, McDermott MP, Rubin HR. The value of patient-reported health status in predicting short-term outcomes after coronary artery bypass graft surgery. *Med Care*. 2002;40(11):1090-1100.
48. Onken JE, Friedman JY, Subramanian S, et al. Treatment patterns and costs associated with sessile colorectal polyps. *Am J Gastroenterol*. 2002;97(11):2896-2901.
49. LaPointe NM, Kramer JM, Weinfurt KP, Califf RM. Practitioner acceptance of the dofetilide risk-management program. *Pharmacotherapy*. 2002;22(8):1041-1046.
50. Schulman KA. Understanding attitudes toward clinical research. *J Ambul Care Manage*. 2003;26(1):88-90.
51. Al-Khatib SM, LaPointe NM, Curtis LH, et al. Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. *Am J Cardiol*. 2003;91(1):91-94.
52. Castel LD, Timbie JW, Sendersky V, Curtis LH, Feather KA, Schulman KA. Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for uncompensated care. *BMC Health Serv Res*. 2003;3(1):1.
53. Schulman KA, Seils DM, Califf RM. Clinical-trial agreements between medical schools and industry. *N Engl J Med*. 2003;348(5):476-478.
54. Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. *Am J Med*. 2003;114(2):135-141.
55. Law AW, Reed SD, Sundry JS, Schulman KA. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. *J Allergy Clin Immunol*. 2003;111(2):296-300.
56. Schulman KA, Stadtmauer EA, Reed SD, et al. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. *Bone Marrow Transplant*. 2003;31(3):205-210.
57. Schulman KA, Seils DM. Outcomes research in oncology: improving patients' experiences with cancer treatment. *Clin Ther*. 2003;25(2):665-670.
58. Polsky D, Mandelblatt JS, Weeks JC, et al. Economic evaluation of breast cancer treatment: considering the value of patient choice. *J Clin Oncol*. 2003;21(6):1139-1146.
59. Weinfurt KP, Castel LD, Li Y, et al. The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. *Cancer*. 2003;98(1):166-175.
60. Reed SD, Friedman JY, Gnanasakthy A, Schulman KA. Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. *Int J Technol Assess Health Care*. 2003;19(2):396-406.
61. Meropol NJ, Weinfurt KP, Burnett CB, et al. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. *J Clin Oncol*. 2003;21(13):2589-2596.
62. Shah BR, Reed SD, Francis J, Ridley DB, Schulman KA. The cost of inefficiency in US hospitals, 1985-1997. *J Health Care Finance*. 2003;30(1):1-9.
63. Sloan FA, Trogdon JG, Curtis LH, Schulman KA. Does the ownership of the admitting hospital make a difference? Outcomes and process of care of Medicare beneficiaries admitted with acute myocardial infarction. *Med Care*. 2003;41(10):1193-1205.
64. Weinfurt KP, Sulmasy DP, Schulman KA, Meropol NJ. Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. *Theor Med Bioeth*. 2003;24(4):329-344.
65. Reed SD, Dillingham PW, Briggs AH, Veenstra DL, Sullivan SD. A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. *Med Decis Making*. 2003;23(3):252-264.
66. Weinfurt KP. Outcomes research related to patient decision making in oncology. *Clin Ther*. 2003;25(2):671-683.
67. Rathore SS, Weinfurt KP, Gross CP, Krumholz HM. Validity of a simple ST-elevation acute myocardial infarction risk index: Are randomized trial prognostic estimates generalizable to elderly patients? *Circulation*. 2003;107(6):811-816.
68. Meropol NJ, Weinfurt KP, Schulman KA. In reply--Phase I trials: physician and patient perceptions. *J Clin Oncol*. 2003;21(24):4659-4660.
69. Wang SS, Mendelson DN, Schulman KA, Mark DB. Exploring options for improving healthcare. *Am Heart J*. 2004;147(1):23-30.
70. Schulman KA. Commentary: Garson's "Physicians, coverage, quality, and cost: the intertwined caduceus." *J Am Coll Cardiol*. 2004;43(1):6-7.
71. Bundorf MK, Schulman KA, Stafford JA, Gaskin D, Jollis JG, Escarce JJ. Impact of managed care on the treatment, costs, and outcomes of fee-for-service Medicare patients with acute myocardial infarction. *Health Serv Res*. 2004;39(1):131-152.
72. Sloan FA, Trogdon JG, Curtis LH, Schulman KA. The effect of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction. *J Am Geriatr Soc*. 2004;52(2):173-181.

73. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. *Med Care*. 2004;42(2):164-175.
74. Meropol NJ, Castel LD, Schulman KA, Weinfurt KP. In reply--Physician-patient communication in Phase I cancer trials. *J Clin Oncol*. 2004;22(3):572-573.
75. Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. *J Urol*. 2004;171(4):1537-1542.
76. Weinfurt KP. Discursive versus information-processing perspectives on a bioethical problem: the case of "unrealistic" patient expectations. *Theory Psychol*. 2004;14(2):191-203.
77. Liao L, Whellan DJ, Tabuchi K, Schulman KA. Differences in care-seeking behavior for acute chest pain in the United States and Japan. *Am Heart J*. 2004;147(4):630-635.
78. Curtis LH, Law AW, Anstrom KJ, Schulman KA. The insurance effect on prescription drug expenditures among the elderly: findings from the 1997 Medical Expenditure Panel Survey. *Med Care*. 2004;42(5):439-446.
79. Massie BM, Krol WF, Ammon SE, et al. The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics. *J Card Fail*. 2004;10(2):101-112.
80. Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. *Pharmacoeconomics*. 2004;22(6):345-361.
81. Harpole LH, Oddone EZ, Stechuchak KM, Schulman KA. Technologies for receiving test results in primary care practices and the impact of managed care. *J Clin Outcomes Manag*. 2004;11(4):216-222.
82. Torti FM Jr, Gwyther LP, Reed SD, Friedman JY, Schulman KA. A multinational review of recent trends and reports in dementia caregiver burden. *Alzheimer Dis Assoc Disord*. 2004;18(2):99-109.
83. Rao SV, Schulman KA, Curtis LH, Gersh BJ, Jollis JG. Socioeconomic status and outcome following acute myocardial infarction in elderly patients. *Arch Intern Med*. 2004;164(10):1128-1133.
84. Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). *Am Heart J*. 2004;148(1):122-128.
85. Patel MR, Meine TJ, Radeva J, et al. State-mandated continuing medical education and the use of proven therapies in patients with an acute myocardial infarction. *J Am Coll Cardiol*. 2004;44(1):192-198.
86. Ridley DB, Schulman KA. Differential pricing of pharmaceuticals in the Internet age. *J Ambul Care Manage*. 2004;27(3):210-214.
87. Curtis LH, Ostbye T, Sendersky V, et al. Inappropriate prescribing for elderly Americans in a large outpatient population. *Arch Intern Med*. 2004;164(15):1621-1625.
88. Guller U, Jain N, Curtis LH, Oertli D, Heberer M, Pietrobon R. Insurance status and race represent independent predictors of undergoing laparoscopic surgery for appendicitis: secondary data analysis of 145,546 patients. *J Am Coll Surg*. 2004;199(4):567-575.
89. Kansagra SM, Curtis LH, Schulman KA. Regionalization of percutaneous transluminal coronary angioplasty and implications for patient travel distance. *JAMA*. 2004;292(14):1717-1723.
90. Hong TB, Oddone EZ, Weinfurt KP, Friedman JY, Schulman KA, Bosworth HB. The relationship between perceived barriers to healthcare and self-rated health. *Psychol Health Med*. 2004;9(4):476-482.
91. Reed SD, Radeva JI, Schulman KA. Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. *J Urol*. 2004;172(5 Pt 1):2082.
92. Friedman JY, Reed SD, Weinfurt KP, Kahler KH, Walter EB, Schulman KA. Parents' reported preference scores for childhood atopic dermatitis disease states. *BMC Pediatr*. 2004;4(1):21.
93. Gaskin DJ, Weinfurt KP, Castel LD, et al. An exploration of relative health stock in advanced cancer patients. *Med Decis Making*. 2004;24(6):614-624.
94. Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of imatinib versus interferon- α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. *Cancer*. 2004;101(11):2574-2583.
95. Anstrom KJ, Reed SD, Allen AS, Glendenning GA, Schulman KA. Long-term survival estimates for imatinib versus interferon- α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. *Cancer*. 2004;101(11):2584-2592.
96. Luo X, Pietrobon R, Curtis LH, Hey LA. Prescription of nonsteroidal anti-inflammatory drugs and muscle relaxants for back pain in the United States. *Spine*. 2004;29(23):E531-E537.
97. Seils DM, Schulman KA. Perceptions of racial and ethnic differences in access to healthcare. *N C Med J*. 2004;65(6):350-352.
98. Schulman KA. Commentary: The unknown benefit of complementary and alternative medicine. *J Altern Complement Med*. 2004;10(6):911.
99. Weinfurt KP, DePuy V, Castel LD, Sulmasy DP, Schulman KA, Meropol NJ. Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials. *Cancer*. 2005;103(1):140-147.
100. Radeva JI, Reed SD, Kalo Z, et al. Economic evaluation of everolimus vs. azathioprine at one year after *de novo* heart transplantation. *Clin Transplant*. 2005;19(1):122-129.
101. Sloan FA, Allsbrook JS, Madre LK, Masselink LE, Mathews CA. States' allocations of funds from the tobacco master settlement agreement. *Health Aff (Millwood)*. 2005;24(1):220-227.
102. Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. *Am J Clin Oncol*. 2005;28(1):8-16.
103. Voils CI, Oddone EZ, Weinfurt KP, Friedman JY, Schulman KA, Bosworth HB. Who trusts healthcare institutions? Results from a community-based sample. *Ethn Dis*. 2005;15(1):97-103.
104. Reed SD, Friedman JY, Engemann JJ, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible *Staphylococcus aureus* bacteremia. *Infect Control Hosp Epidemiol*. 2005;26(2):175-183.
105. Reed SD, Anstrom KJ, Bakhai A, et al. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. *Am Heart J*. 2005;149(3):434-443.
106. Eisenstein EL, Lemons PW, Tardiff BE, Schulman KA, Jolly MK, Califf RM. Reducing the costs of phase III cardiovascular clinical trials. *Am Heart J*. 2005;149(3):482-488.
107. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. *Ann Oncol*. 2005;16(4):579-584.
108. Curtis LH, Masselink LE, Ostbye T, et al. Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. *Arch Pediatr Adolesc Med*. 2005;159(4):362-366.

109. Whellan DJ, Hasselblad V, Peterson E, O'Connor CM, Schulman KA. Metaanalysis and review of heart failure disease management randomized controlled clinical trials. *Am Heart J*. 2005;149(4):722-729.
110. Yancy WS Jr, Olsen MK, Curtis LH, Schulman KA, Cuffe MS, Oddone EZ. Variations in coronary procedure utilization depending on body mass index. *Arch Intern Med*. 2005;165(12):1381-1387.
111. Engemann JJ, Friedman JY, Reed SD, et al. Clinical outcomes and costs due to *Staphylococcus aureus* bacteremia among patients receiving long-term hemodialysis. *Infect Control Hosp Epidemiol*. 2005;26(6):534-539.
112. Ostbye T, Curtis LH, Masselink LE, et al. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. *Pharmacoepidemiol Drug Saf*. 2005;14(6):407-415.
113. Van Houtven CH, Voils CI, Oddone EZ, et al. Perceived discrimination and reported delay of pharmacy prescriptions and medical tests. *J Gen Intern Med*. 2005;20(7):578-583.
114. Chang J, Kauf TL, Mahajan S, et al. Impact of disease severity and gastrointestinal side effects on the health state preferences of patients with osteoarthritis. *Arthritis Rheum*. 2005;52(8):2366-2375.
115. Mausekopf J, Kitahata M, Kauf T, Richter A, Tolson J. HIV antiretroviral treatment: early versus later. *J Acquir Immune Defic Syndr*. 2005;39(5):562-569.
116. Reed SD, Radeva JI, Weinfurt KP, et al. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). *Am Heart J*. 2005;150(2):323-329.
117. Radeva JI, VanScoyoc E, Smith FO, Curtis LH, Breitfeld PP. National estimates of the use of hematopoietic stem-cell transplantation in children with cancer in the United States. *Bone Marrow Transplant*. 2005;36(5):397-404.
118. Friedman JY, Anstrom KJ, Weinfurt KP, et al. Perceived racial/ethnic bias in health care in Durham County, North Carolina: a comparison of community and national samples. *N C Med J*. 2005;66(4):267-275.
119. Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA. Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. *Curr Med Res Opin*. 2005;21(10):1527-1533.
120. Rathore SS, Weinfurt KP, Foody JM, Krumholz HM. Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients. *Am Heart J*. 2005;150(3):402-410.
121. Meine TJ, Patel MR, DePuy V, et al. Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction. *Ann Intern Med*. 2005;143(7):481-485.
122. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. *Value Health*. 2005;8(5):521-533.
123. Rasiel EB, Weinfurt KP, Schulman KA. Can prospect theory explain risk-seeking behavior by terminally ill patients? *Med Decis Making*. 2005;25(6):609-613.
124. Ginsburg GS, Konstance RP, Allsbrook JS, Schulman KA. Implications of pharmacogenomics for drug development and clinical practice. *Arch Intern Med*. 2005;165(20):2331-2336.
125. Goodman L, Dutton MA, Vankos N, Weinfurt K. Women's resources and use of strategies as risk and protective factors for reabuse over time. *Violence Against Women*. 2005;11(3):311-336.
126. Dutton MA, Kaltman S, Goodman LA, Weinfurt K, Vankos N. Patterns of intimate partner violence: correlates and outcomes. *Violence Vict*. 2005;20(5):483-497.
127. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL. Trends in health care resource use for hepatitis C virus infection in the United States. *Hepatology*. 2005;42(6):1406-1413.
128. Chu VH, Crosslin DR, Friedman JY, et al. *Staphylococcus aureus* bacteremia in patients with prosthetic devices: costs and outcomes. *Am J Med*. 2005;118(12):1416.
129. Weinfurt KP. Experience, grammar, and the stuff of psychology. *Theory Psychol*. 2005;15(3):407-409.
130. Voils CI, Oddone EZ, Weinfurt KP, et al. Racial differences in health concern. *J Natl Med Assoc*. 2006;98(1):36-42.
131. Kauf TL, Velazquez EJ, Crosslin DR, et al. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. *Am Heart J*. 2006;151(1):206-212.
132. Liao L, Jollis JG, Anstrom KJ, et al. Costs for heart failure with normal vs reduced ejection fraction. *Arch Intern Med*. 2006;166(1):112-118.
133. Schulman KA. Medicare and cost-effectiveness analysis. *N Engl J Med*. 2006;354(2):207-209.
134. Weinfurt KP, Dinan MA, Allsbrook JS, et al. Policies of academic medical centers for disclosing financial conflicts of interest to potential research participants. *Acad Med*. 2006;81(2):113-118.
135. Sung JC, Curtis LH, Schulman KA, Albala DM. Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia. *J Urol*. 2006;175(3 Pt 1):1023-1027.
136. McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). *J Am Coll Cardiol*. 2006;47(4):726-733.
137. Glickman SW, Rasiel EB, Hamilton CD, Kubataev A, Schulman KA. A portfolio model of drug development for tuberculosis. *Science*. 2006;311(5765):1246-1247.
138. Ridley DB, Kramer JM, Tilson HH, Grabowski HG, Schulman KA. Spending on postapproval drug safety. *Health Aff (Millwood)*. 2006;25(2):429-436.
139. Alexander BD, Ashley ED, Reller LB, Reed SD. Cost savings with implementation of PNA FISH testing for identification of *Candida albicans* in blood cultures. *Diagn Microbiol Infect Dis*. 2006;54(4):277-282.
140. Jhaveri R, Grant W, Kauf TL, McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. *J Pediatr*. 2006;148(3):353-358.
141. Inrig JK, Reed SD, Szczech LA, et al. Relationship between clinical outcomes and vascular access type among hemodialysis patients with *Staphylococcus aureus* bacteremia. *Clin J Am Soc Nephrol*. 2006;1(3):518-524.
142. Curtis LH, Stoddard J, Radeva JI, et al. Geographic variation in the prescription of Schedule II opioid analgesics among outpatients in the United States. *Health Serv Res*. 2006;41(3 Pt 1):837-855.
143. Reed SD, Radeva JI, Daniel DB, et al. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial. *Pharmacoeconomics*. 2006;24(5):479-494.
144. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. *Ann Oncol*. 2006;17(6):986-989.
145. Allen LaPointe NM, Curtis LH, Chan KA, et al. Frequency of high-risk use of QT-prolonging medications. *Pharmacoepidemiol Drug Saf*. 2006;15(6):361-368.

146. Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Albala DM, Moul JW. Prostate specific antigen testing in men older than 75 years in the United States. *J Urol*. 2006;176(2):511-514.
147. Flynn KE, Smith MA, Vanness D. A typology of preferences for participation in healthcare decision making. *Soc Sci Med*. 2006;63(5):1158-1169.
148. Weinfurt KP, Friedman JY, Allsbrook JS, Dinan MA, Hall MA, Sugarman J. Views of potential research participants on financial conflicts of interest: barriers and opportunities for effective disclosure. *J Gen Intern Med*. 2006;21(9):901-906.
149. Reed SD, McMurray JJ, Velazquez EJ, et al. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial infarcTion (VALIANT) trial. *Am Heart J*. 2006;152(3):500-508.
150. Torti FM Jr, Reed SD, Schulman KA. Analytic considerations in economic evaluations of multinational cardiovascular clinical trials. *Value Health*. 2006;9(5):281-291.
151. Reed SD, Califf RM, Schulman KA. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation. *Health Aff (Millwood)*. 2006;25(5):1309-1317.
152. Weinfurt KP, Friedman JY, Dinan MA, et al. Disclosing conflicts of interest in clinical research: views of institutional review boards, conflict of interest committees, and investigators. *J Law Med Ethics*. 2006;34(3):581-591, 481.
153. Hall MA, Camacho F, Lawlor JS, DePuy V, Sugarman J, Weinfurt K. Measuring trust in medical researchers. *Med Care*. 2006;44(11):1048-1053.
154. Flynn KE, Smith MA, Freese J. When do older adults turn to the Internet for health information? Findings from the Wisconsin Longitudinal Study. *J Gen Intern Med*. 2006;21(12):1295-1301.
155. Dinan MA, Weinfurt KP, Friedman JY, et al. Comparison of conflict of interest policies and reported practices in academic medical centers in the United States. *Account Res*. 2006;13(4):325-342.
156. Curtis LH, Schulman KA. Overregulation of health care: musings on disruptive innovation theory. *Law Contemp Probl*. 2006;69(4):195-206.
157. Califf RM, Harrington RA, Madre LK, Peterson ED, Roth D, Schulman KA. Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. *Health Aff (Millwood)*. 2007;26(1):62-74.
158. Meropol NJ, Schulman KA. Perspectives on the cost of cancer care. *J Clin Oncol*. 2007;25(2):169-170.
159. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. *J Clin Oncol*. 2007;25(2):180-186.
160. Weinfurt KP. Value of high-cost cancer care: a behavioral science perspective. *J Clin Oncol*. 2007;25(2):223-227.
161. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. *JAMA*. 2007;297(2):159-168.
162. Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Dahm P, Moul JW. Relationship between body mass index and prostate cancer screening in the United States. *J Urol*. 2007;177(2):493-498.
163. Whellan DJ, Reed SD, Liao L, Gould SD, O'Connor CM, Schulman KA. Financial implications of a model heart failure disease management program for providers, hospital, healthcare systems, and payer perspectives. *Am J Cardiol*. 2007;99(2):256-260.
164. Whellan DJ, O'Connor CM, Lee KL, et al. Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION): design and rationale. *Am Heart J*. 2007;153(2):201-211.
165. Liao L, Anstrom KJ, Gottdiener JS, et al. Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. *Am Heart J*. 2007;153(2):245-252.
166. Weinfurt KP, Allsbrook JS, Friedman JY, et al. Developing model language for disclosing financial interests to potential clinical research participants. *IRB*. 2007;29(1):1-5.
167. Kansagra SM, Curtis LH, Anstrom KJ, Schulman KA. Trends in operator and hospital procedure volume and outcomes for percutaneous transluminal coronary angioplasty, 1996 to 2001. *Am J Cardiol*. 2007;99(3):339-343.
168. Li JS, Eisenstein EL, Grabowski HG, et al. Economic return of clinical trials performed under the pediatric exclusivity program. *JAMA*. 2007;297(5):480-488.
169. Scales CD Jr, Curtis LH, Norris RD, et al. Changing gender prevalence of stone disease. *J Urol*. 2007;177(3):979-982.
170. Glickman SW, Rasiel EB, Hamilton CD, Schulman KA. Developing drugs for tuberculosis. *Science*. 2007;315(1076):1077.
171. Brown TT, Scheffler RM, Tom SE, Schulman KA. Does the market value racial and ethnic concordance in physician-patient relationships? *Health Serv Res*. 2007;42(2):706-726.
172. Turer AT, Mahaffey KW, Compton KL, Califf RM, Schulman KA. Publication or presentation of results from multicenter clinical trials: evidence from an academic medical center. *Am Heart J*. 2007;153(4):674-680.
173. Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier. *Qual Life Res*. 2007;16(4):717-723.
174. Shea AM, DePuy V, Allen JM, Weinfurt KP. Use and perceptions of clinical practice guidelines by internal medicine physicians. *Am J Med Qual*. 2007;22(3):170-176.
175. Glickman SW, Ou FS, DeLong ER, et al. Pay for performance, quality of care, and outcomes in acute myocardial infarction. *JAMA*. 2007;297(21):2373-2380.
176. Reed SD, Califf RM, Schulman KA. Is there a price to pay for short-term savings in the clinical development of new pharmaceutical products? *Drug Inf J*. 2007;41(4):491-499.
177. Meropol NJ, Schulman KA. In reply--Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab. *J Clin Oncol*. 2007;25(22):3383.
178. Brown AJ, Seils DM, Thompson PM. Access and diversity in academic mentoring. *JAMA*. 2007;298(7):739.
179. Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologics. *Managerial and Decision Economics*. 2007;28(4-5):439-451.
180. Friedman JY, Sugarman J, Dhillon JK, et al. Perspectives of clinical research coordinators on disclosing financial conflicts of interest to potential research participants. *Clin Trials*. 2007;4(3):272-278.
181. DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. *Support Care Cancer*. 2007;15(7):869-876.
182. Curtis LH, Hammill BG, Bethel MA, Anstrom KJ, Gottdiener JS, Schulman KA. Costs of the metabolic syndrome in elderly individuals: findings from the Cardiovascular Health Study. *Diabetes Care*. 2007;30(10):2553-2558.
183. Flynn KE, Smith MA. Personality and health care decision-making style. *J Gerontol B Psychol Sci Soc Sci*. 2007;62(5):261-267.
184. Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. *Med Care*. 2007;45(Suppl 2):S103-S107.

185. Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. *JAMA*. 2007;298(13):1517-1524.
186. Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. *JAMA*. 2007;298(13):1525-1532.
187. Shah BR, Glickman SW, Liang L, et al. The impact of for-profit hospital status on the care and outcomes of patients with non-ST-segment elevation myocardial infarction: results from the CRUSADE initiative. *J Am Coll Cardiol*. 2007;50(15):1462-1468.
188. Friedman JY, Curtis LH, Hammill BG, et al. The Medicare Modernization Act and reimbursement for outpatient chemotherapy: Do patients perceive changes in access to care? *Cancer*. 2007;110(10):2304-2312.
189. Garcia SF, Cella D, Clauser SB, et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: a Patient-Reported Outcomes Measurement Information System initiative. *J Clin Oncol*. 2007;25(32):5106-5112.
190. Glickman SW, Baggett KA, Krubert CG, Peterson ED, Schulman KA. Promoting quality: the health-care organization from a management perspective. *Int J Qual Health Care*. 2007;19(6):341-348.
191. Glickman SW, Boulding W, Staelin R, et al. A framework for quality improvement: an analysis of factors responsible for improvement at hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. *Am Heart J*. 2007;154(6):1206-1220.
192. Shea AM, Reed SD, Curtis LH, Alexander MJ, Villani JJ, Schulman KA. Characteristics of nontraumatic subarachnoid hemorrhage in the United States in 2003. *Neurosurgery*. 2007;61(6):1131-1138.
193. Scales CD Jr, Moul JW, Curtis LH, Elkin EP, Hughes ME, Carroll PR. Prostate cancer in the Baby Boomer generation: results from CaPSURE. *Urology*. 2007;70(6):1162-1167.
194. Williams JE, Anstrom KJ, Friedman JY, Schulman KA. Racial/ethnic variation in perceptions of medical information sources in Durham County, North Carolina. *N C Med J*. 2007;68(6):391-398.
195. Curtis LH, Hammill BG, Bethel MA, et al. Pancreatic beta-cell function as a predictor of cardiovascular outcomes and costs: findings from the Cardiovascular Health Study. *Curr Med Res Opin*. 2008;24(1):41-50.
196. Reed SD, Shea AM, Schulman KA. Economic implications of potential changes to regulatory and reimbursement policies for medical devices. *J Gen Intern Med*. 2008;23(Suppl 1):50-56.
197. Sloan FA, Bethel MA, Ruiz D Jr, Shea AH, Feinglos MN. The growing burden of diabetes mellitus in the US elderly population. *Arch Intern Med*. 2008;168(2):192-199.
198. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. *Arch Intern Med*. 2008;168(4):418-424.
199. Cox CE, Reed SD, Govert JA, et al. Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. *Crit Care Med*. 2008;36(3):706-714.
200. Konstance RP, Eisenstein EL, Anstrom KJ, et al. Outcomes of second revascularization procedures after stent implantation. *J Med Syst*. 2008;32(2):177-186.
201. Hammill BG, Curtis LH, Bennett-Guerrero E, et al. Impact of heart failure on patients undergoing major noncardiac surgery. *Anesthesiology*. 2008;108(4):559-567.
202. Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA. Medical costs of abnormal serum sodium levels. *J Am Soc Nephrol*. 2008;19(4):764-770.
203. Glickman SW, Schulman KA, Cairns CB. Primary PCI in ST-segment elevation myocardial infarction [letter]. *N Engl J Med*. 2008;358(16):1751-1752.
204. Erdmann D, Price K, Reed S, Follmar KE, Levin LS, Marcus JR. A financial analysis of operative facial fracture management. *Plast Reconstr Surg*. 2008;121(4):1323-1327.
205. Glickman SW, Schulman KA, Peterson ED, Hocker MB, Cairns CB. Evidence-based perspectives on pay for performance and quality of patient care and outcomes in emergency medicine. *Ann Emerg Med*. 2008;51(5):622-631.
206. Reed SD, Anstrom KJ, Li Y, Schulman KA. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. *Pharmacoeconomics*. 2008;26(5):435-446.
207. Grant WC, Anstrom KJ. Minimizing selection bias in randomized trials: a Nash equilibrium approach to optimal randomization. *J Econ Behav Organ*. 2008;66(3-4):606-624.
208. Weinfurt KP, Seils DM, Tzeng JP, Lin L, Schulman KA, Califf RM. Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents. *PLoS ONE*. 2008;3(5):e2128.
209. Fleisher L, Buzaglo J, Collins M, et al. Using health communication best practices to develop a web-based provider-patient communication aid: The CONNECT™ study. *Patient Educ Couns*. 2008;71(3):378-387.
210. Clem KJ, Promes SB, Glickman SW, et al. Factors enhancing career satisfaction among female emergency physicians. *Ann Emerg Med*. 2008;51(6):723-728.
211. Weinfurt KP, Hall MA, Dinan MA, et al. Effects of disclosing financial interests on attitudes toward clinical research. *J Gen Intern Med*. 2008;23(6):860-866.
212. Glickman SW, Anstrom KJ, Lin L, et al. Challenges in enrollment of minority, pediatric, and geriatric patients in emergency and acute care clinical research. *Ann Emerg Med*. 2008;51(6):775-780.

Before the CCGE: Publications Prior to September 1999

1. Green J, Singer M, Wintfeld N, Schulman K, Passman L. Projecting the impact of AIDS on hospitals. *Health Aff (Millwood)*. 1987;6:19-31.
2. Green J, Singer M, Wintfeld N, Schulman K. AIDS and New England hospitals. *N Engl J Public Policy*. 1987;4:273-283.
3. Merkel PA, Schulman KA. Ranitidine to prevent recurrence of duodenal ulcer [letter]. *N Engl J Med*. 1989;321:835-836.
4. Schulman K. Screening for colorectal cancer [letter]. *Ann Intern Med*. 1990;113:333-334.
5. Schulman KA, Kinoshian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. *JAMA*. 1990;264:3025-3033.
6. Schulman KA, Glick HA, Rubin H, Eisenberg JM. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis: economic assessment of a new therapeutic agent. *JAMA*. 1991;266:3466-3471.
7. Greco PJ, Schulman KA, Lavizzo-Mourey R, Hansen-Flaschen J. The Patient Self-Determination Act and the future of advance directives. *Ann Intern Med*. 1991;115:639-643.
8. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. *Ann Intern Med*. 1991;114:798-802.
9. Hennessy S, Fogarty PM, Schulman KA, Mignott H. Gastric obstruction with extended-release tablets. *DICP*. 1991;25:678-679.
10. Lynn LA, Schulman KA, Eisenberg JM. The pharmacoeconomics of HIV disease. *Pharmacoeconomics*. 1992;1:161-174.
11. Schulman KA, Escarce JJ, Eisenberg JM, et al. Assessing physicians' estimates of the probability of coronary artery disease: the influence of patient characteristics. *Med Decis Making*. 1992;12:109-114.
12. Seltzer E, Schulman KA, Brennan PJ, Lynn LA. Patient attitudes toward rooming with persons with HIV infection. *J Fam Pract*. 1993;37:564-568.
13. Schulman KA, McDonald RC, Lynn LA, Frank I, Christakis NA, Schwartz JS. Screening surgeons for HIV infection: assessment of a potential public health program. *Infect Control Hosp Epidemiol*. 1994;15:147-155.
14. Schulman K, Sulmasy DP, Roney D. Ethics, economics, and the publication policies of major medical journals. *JAMA*. 1994;272:154-156.
15. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. *Stroke*. 1994;25:1721-1725.
16. Roulidis ZC, Schulman KA. Physician communication in managed care organizations: opinions of primary care physicians. *J Fam Pract*. 1994;39:446-451.
17. Glick H, Kinoshian B, Schulman K. Decision analytic modeling: some uses in the evaluation of new pharmaceuticals. *Drug Inf J*. 1994;28:691-707.
18. Schulman KA, Glick HA, Yabroff KR, Eisenberg JM. Introduction to clinical economics: assessment of cancer therapies. *J Natl Cancer Inst Monogr*. 1995;(19):1-9.
19. Schulman KA, Glick HA. Economic evaluation of high-dose chemotherapy and bone marrow transplantation for patients with breast cancer of stage II or IIIA with more than 10 positive lymph nodes at surgical excision. *J Natl Cancer Inst Monogr*. 1995;(19):45-50.
20. Lee JH, Glick HA, Kinoshian B, Schulman KA. An interactive computer system for formulary management using cost-effectiveness analysis. *MD Comput*. 1995;12:59-65.
21. Schulman K. Cost-effectiveness analyses [letter]. *N Engl J Med*. 1995;332:124.
22. Schulman KA, Rubenstein LE, Chesley FD, Eisenberg JM. The roles of race and socioeconomic factors in health services research. *Health Serv Res*. 1995;30:179-195.
23. Schulman KA, Yabroff KR. Measuring the cost-effectiveness of cancer care. *Oncology (Williston Park)*. 1995;9:523-533.
24. Morris CB, Schulman KA. The emerging role of the Food and Drug Administration in pharmacoeconomic evaluation during the drug development process. *Drug Inf J*. 1995;29:1105-1111.
25. Schulman KA, Yabroff KR, Glick H. A health services approach for the evaluation of innovative pharmaceutical and biotechnology products. *Drug Inf J*. 1995;29:1405-1414.
26. Schulman KA, Rubenstein LE, Glick HA, Eisenberg JM. Relationships between sponsors and investigators in pharmacoeconomic and clinical research. *Pharmacoeconomics*. 1995;7:206-220.
27. Schulman KA. Book Review. Health Politics--The Politics of Health Care Reform: Lessons From the Past, Prospects for the Future; Edited by James A. Morone and Gary S. Belkin. *N Engl J Med*. 1995;332:195.
28. Yabroff KR, Linas BP, Schulman K. Evaluation of quality of life for diverse patient populations. *Breast Cancer Res Treat*. 1996;40:87-104.
29. Schulman KA. Economics of bone marrow transplantation. *J Clin Oncol*. 1996;14:1409-1410.
30. Schulman KA, Rubenstein LE, Abernethy DR, Seils DM, Sulmasy DP. The effect of pharmaceutical benefits managers: Is it being evaluated? *Ann Intern Med*. 1996;124:906-913.
31. Lerman C, Narod S, Schulman K, et al. *BRCAl* testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. *JAMA*. 1996;275:1885-1892.
32. Hirsh JA, Langlotz CP, Lee J, Tanio CP, Grossman RI, Schulman KA. Clinical assessment of MR of the brain in nonsurgical patients. *Am J Neuroradiol*. 1996;17:1245-1253.
33. Schulman KA, Glick H, Buxton M, et al. The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial. *Control Clin Trials*. 1996;17:304-315.
34. Knollmann BC, Corson AP, Twigg HL, Schulman KA. Assessment of joint review of radiologic studies by a primary care physician and a radiologist. *J Gen Intern Med*. 1996;11:608-612.
35. Schulman KA, Buxton M, Glick H, et al. Results of the economic evaluation of the FIRST study: a multinational prospective economic evaluation. Flolan International Randomized Survival Trial. *Int J Technol Assess Health Care*. 1996;12:698-713.
36. Schulman KA, Llana T, Yabroff KR. Economic assessment within the clinical development program. *Med Care*. 1996;34:DS89-DS95.
37. DeChant HK, Tohme WG, Mun SK, Hayes WS, Schulman KA. Health systems evaluation of telemedicine: a staged approach. *Telemed J*. 1996;2:303-312.
38. Mauskopf J, Schulman K, Bell L, Glick H. A strategy for collecting pharmacoeconomic data during phase II/III clinical trials. *Pharmacoeconomics*. 1996;9:264-277.
39. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. *BMJ*. 1996;313:275-283.
40. Schulman KA. Understanding the economic savings and costs of periodic mammographic screening in the workplace. *Oncology*. 1996;10:285-284.
41. Tom E, Schulman KA. Mathematical models in decision analysis. *Infect Control Hosp Epidemiol*. 1997;18:65-73.
42. Schulman KA, Linas BP. Pharmacoeconomics: state of the art in 1997. *Annu Rev Public Health*. 1997;18:529-548.

43. Schulman KA, Rubenstein LE, Seils DM, Harris M, Hadley J, Escarce JJ. Quality assessment in contracting for tertiary care services by HMOs: a case study of three markets. *Jt Comm J Qual Improv.* 1997;23:117-127.
44. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. *Health Econ.* 1997;6:243-252.
45. Mitchell JM, Meehan KR, Kong J, Schulman KA. Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. *J Clin Oncol.* 1997;15:2644-2651.
46. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Development and validation of a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trials. *J Allergy Clin Immunol.* 1997;100:16-22.
47. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). *Am Heart J.* 1997;134:44-54.
48. Roulidis ZC, DeChant HK, Schulman KA. Resource utilization control processes as indicators of quality in managed care organizations: a proposal. *Am J Med.* 1997;103:146-151.
49. Winchester JF, Tohme WG, Schulman KA, Collmann J, Johnson A, Meissner MC et al. Hemodialysis patient management by telemedicine: design and implementation. *ASAIO J.* 1997;43:M763-M766.
50. Tohme WG, Winchester JF, Collmann J, et al. Remote management of haemodialysis patients: design and implementation of a telemedicine network. *Minim Invasive Ther Allied Technol.* 1997;5/6:421-428.
51. Schulman KA, Johnson AE, Rathore SS. The use of satisfaction measures in oncology. *ASCO Educational Book.* 1997;Spring:337-341.
52. Schulman KA. Coronary angioplasty had a lower 5-year cost than bypass surgery only in patients with 2-vessel coronary disease. *ACP J Club.* 1997;127:25.
53. Gaskin DJ, Kong J, Meropol NJ, Yabroff KR, Weaver C, Schulman KA. Treatment choices by seriously ill patients: the Health Stock Risk Adjustment model. *Med Decis Making.* 1998;18:84-94.
54. Glick HA, Polsky D, Willke RJ, Alves WM, Kassell N, Schulman K. Comparison of the use of medical resources and outcomes in the treatment of aneurysmal subarachnoid hemorrhage between Canada and the United States. *Stroke.* 1998;29:351-358.
55. Glick H, Willke R, Polsky D, et al. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage: economic evaluation of a phase III clinical trial in Europe and Australia. *Int J Technol Assess Health Care.* 1998;14:145-160.
56. Sulmasy DP, Linas BP, Gold KF, Schulman KA. Physician resource use and willingness to participate in assisted suicide. *Arch Intern Med.* 1998;158:974-978.
57. Schulman KA, Dorsainvil D, Yabroff KR, et al. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. *Bone Marrow Transplant.* 1998;21:607-614.
58. Schulman KA, Mark DB, Califf RM. Outcomes and costs within a disease management program for advanced congestive heart failure. *Am Heart J.* 1998;135:S285-S292.
59. Brown M, Glick HA, Harrell F, et al. Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology economics workbook. *J Natl Cancer Inst Monogr.* 1998;1-28.
60. Neymark N, Kiebert W, Torfs K, et al. Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop. *Eur J Cancer.* 1998;34:1317-1333.
61. Schulman K, Burke J, Drummond M, et al. Resource costing for multinational neurologic clinical trials: methods and results. *Health Econ.* 1998;7:629-638.
62. Rathore SS, Mehta SS, Boyko WL Jr, Schulman KA. Prescription medication use in older Americans: a national report card on prescribing. *Fam Med.* 1998;30:733-739.
63. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. *Health Econ.* 1998;7:481-493.
64. Schulman KA, Boyko WL Jr. Evaluating cancer costs in NCI trials. *Cancer Treat Res.* 1998;97:37-52.
65. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. *N Engl J Med.* 1999;340:618-626.
66. Schulman KA, Berlin JA, Escarce JJ. Race, sex, and physicians' referrals for cardiac catheterization [letter]. *N Engl J Med.* 1999;341:285-287.
67. Schulman KA, Ohishi A, Park J, Glick HA, Eisenberg JM. Clinical economics in clinical trials: the measurement of cost and outcomes in the assessment of clinical services through clinical trials. *Keio J Med.* 1999;48:1-11.
68. Schulman KA, Yabroff KR, Kong J, et al. A claims data approach to defining an episode of care. *Health Serv Res.* 1999;34:603-621.
69. De Jonge KE, Sulmasy DP, Gold KG, et al. The timing of do-not-resuscitate orders and hospital costs. *J Gen Intern Med.* 1999;14:190-192.
70. Boyko WL Jr, Glick HA, Schulman KA. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data. *Am Heart J.* 1999;137:S115-S119.
71. Schulman KA, Birch R, Zhen B, Pania N, Weaver CH. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. *J Clin Oncol.* 1999;17:1227-1233.
72. Berger AK, Schulman KA, Gersh BJ, et al. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. *JAMA.* 1999;282:341-348.
73. Schulman KA, Abernethy DR, Rathore SS, Woosley RL. Regulating manufacturer-affiliated communication in the information age. *Clin Pharmacol Ther.* 1999;65:593-597.
74. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Item responsiveness of a rhinitis and asthma symptom score during a pollen season. *J Asthma.* 1999;36:459-465.
75. Mehta SS, Wilcox CS, Schulman KA. Treatment of hypertension in patients with comorbidities: results from the Study of Hypertensive Prescribing Practices (SHyPP). *Am J Hypertens.* 1999;12:333-340.
76. Mehta SS, Suzuki S, Glick HA, Schulman KA. Determining an episode of care using claims data: diabetic foot ulcer. *Diabetes Care.* 1999;22:1110-1115.